Atlas Venture Life Science Advisors, LLC
Atlas Venture Fund XIII, L.P.
Late investment period
Late investment period: first sale Mar 2022, per Form D (fund age approximates vintage)
- Vintage
- 2022
- Fund size
- $450M to $535.4M (Form D and SEC adviser filing)
- Stages
- Not stated
- Sectors
- Biotech
- Regions
- Not stated
01 · Thesis
Atlas Venture creates and builds breakthrough biotechnology companies in life sciences, partnering with life science entrepreneurs and launching startups from its incubator to translate groundbreaking science into new medicines.Inferred from the firm's website
02 · Initial check
$4.5M to $8.92M (estimated from fund size)
Estimated from Form D and SEC adviser filing
03 · Who to approach
Named on this fund's Form D
- David Grayzel, MD, Partner
- Jason Rhodes, Partner
- Kevin Bitterman, PhD, Partner
- Jean-François Formela, MD, Partner
- Michael Gladstone, Partner
- Bruce Booth, Partner
04 · Deals
No deals attributed to this fund yet.
05 · Evidence
Firm-wideAtlas Venture builds breakthrough biotechnology companies in life sciences.
We build breakthrough biotechnology companies
https://atlasventure.com/
06 · Sources
Last verified: Oct 28, 2026